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well as our own experience, demonstrate the reluctance
of physicians to up-titrate nitroglycerin doses, especially
in patients being treated without hemodynamic monitor-
ing.1 Our findings also reflect the temporary nature of the
nitrate-induced hemodynamic effect because of the early
development of tolerance8,9 Attenuation of effect with
continuous vascular exposure to nitrates has recently
been suggested to be caused by increased production of
oxygen-free radicals, which leads to decreased bioavail-
ability of nitrate-derived nitric oxide10,11 and a negative
effect on the function of nitric oxide synthase, the en-
zyme responsible for endothelial control of vascular
tone.12,13
This study represents a subgroup analysis of data
from 1 individual center participating in the VMAC
study. As such, the results are limited by a relatively
small sample size and the derivative experience. In ad-
dition, although the maximum mean dose of nitroglyc-
erin used at this site was high relative to that for all sites
participating in the VMAC study, even higher doses may
be used in clinical practice. Higher doses of nitroglycerin
may have similar or different clinical outcomes.
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We undertook a meta-analysis of large, randomized
controlled trials in hypertensive subjects that com-
pared angiotensin-converting enzyme (ACE) inhibi-
tors with different classes of antihypertensive drugs.
Compared with subjects randomized to drugs differ-
ent from ACE inhibitors, those treated with ACE inhib-
itors did not show a different risk of congestive heart
failure (CHF) (odds ratio 1.03, 95% confidence inter-
val 0.96 to 1.12, p  0.407). The degree of protec-
tion from CHF associated with the use of ACE inhibi-
tors showed a nonsignificant trend to increase with
age and the degree of blood pressure control. Thus,
the hypothesis that ACE inhibitors are superior to
other antihypertensive drugs for prevention of CHF in
hypertension remains unproven. 2004 by Ex-
cerpta Medica, Inc.
(Am J Cardiol 2004;93:240–243)
Angiotensin-converting enzyme (ACE) inhibitorsimprove symptoms and prolong survival in pa-
tients with congestive heart failure (CHF). In a meta-
analysis of 7 large studies in patients with CHF or left
ventricular dysfunction, ACE inhibitors were associ-
ated with a significant decrease in a composite of
death, myocardial infarction, and hospital admission
for patients with CHF (odds ratio [OR] 0.72, 95%
confidence interval [CI] 67 to 78).1 However, al-
though the benefits of ACE inhibitors in patients with
CHF are well established, their potential value for
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primary prevention of CHF in patients with hyperten-
sion is still unclear. By blunting the renin–angiotensin
system over the long term, ACE inhibitors might
prevent or delay progression of myocardial fibrosis
and structural disarray in the hypertensive heart,2,3
and, thus may have potential valuable implications for
the prevention of CHF.
• • •
We undertook a meta-analysis of major clinical
trials in hypertension that compared ACE inhibitors
with different antihypertensive drugs in subjects with
primary hypertension. We tested whether treatment
with ACE inhibitors was associated with a lower risk
of CHF. We selected only the studies that met all of
the following prespecified criteria: (1) publication in a
peer-reviewed journal indexed in MEDLINE; (2) in-
clusion of patients with a clinical diagnosis of essen-
tial hypertension; (3) occurrence of CHF as a pre-
specified end point during follow-up; (4) definition of
CHF events in the single studies; (5) assessment of
blood pressure at baseline and at follow-up visits; (6)
randomized controlled design; (7) follow-up of 2
years; and (8) sample size 100 subjects.
Studies were identified through MEDLINE using re-
search methods filters4 with publication dates before
June 30, 2003. The final search identified 6 studies5–11
that fulfilled the inclusion criteria. Two of these studies
had enrolled patients with hypertension and type 2 dia-
betes.8,9 The Analysis of the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) included the reports published in 20006 and
20027 to allow an assessment of the effects of doxazosin6
in addition to other treatments.7 For all studies, we ac-
cepted the definition of CHF events reported in the
individual reports. All outcome results
were reported on the basis of an inten-
tion-to-treat approach.
The reference group was com-
posed of patients randomly assigned
to antihypertensive drugs different
from ACE inhibitors. The OR and
95% CI for CHF were calculated
separately for each of the 6 studies
according to fixed- and random-ef-
fect models. The assumption of ho-
mogeneity between patient studies
was tested using the Zelen’s test.
Analyses were performed using the
Comprehensive Meta-Analysis soft-
ware (Biostat, Englewood, New Jer-
sey). We used the SPSS 11.0 statis-
tical package (SPSS Inc., Chicago,
Illinois) to correlate the ORs of treat-
ment with ACE inhibitors versus other
antihypertensive drugs with the corre-
sponding differences in achieved sys-
tolic blood pressure. For these calcula-
tions, the regression lines were
weighted by the inverse of variance of
patient ORs.
Table 1 lists the main characteris-
tics of the clinical trials. All of the trials—except the
Appropriate Blood Pressure Control in Diabetes9 study,
which enrolled patients affected by type 2 diabetes with
or without hypertension—were conducted in subjects
with hypertension. For the purpose of the present anal-
ysis, we included only the cohort of subjects with hyper-
tension. The age of subjects ranged from 52 to 73 years,
and male gender prevailed (range 33% to 55%). The
duration of follow-up ranged from 4.1 to 8.4 years. At
randomization, none of the subjects had clinical evidence
of CHF in most studies,4–8 whereas 0.3% of subjects in
1 study11 and 1.9% of subjects in another study10 had a
previous diagnosis of CHF.
Overall, there were 3,511 new cases of CHF: 922
among the subjects randomized to ACE inhibitors and
2,589 among the subjects randomized to other antihy-
pertensive drugs. The risk of CHF did not differ between
subjects randomized to receive ACE inhibitors and sub-
jects randomized to receive different classes of antihy-
pertensive drugs (fixed effect: OR 1.03, 95% CI 0.96 to
1.12; p  0.407; random effect: OR 0.98, 95% CI 0.84
to 1.15; p 0.83) (Figure 1). Because of its large sample
size, ALLHAT6,7 exerted a major influence on the over-
all meta-analysis estimate. For example, the OR for CHF
in the lisinopril groups compared with the other non-
ACE groups in ALLHAT was 1.10 (95% CI 1.00 to
1.21) with a p value bordering on significance (p 
0.050). The percentage weight contributed by ALLHAT
to the overall metaanalysis was 68.7%.
• • •
In patient studies, the degree of protection from
CHF, expressed in terms of OR in the ACE inhibitor
group compared with the other group, showed a non-
significant trend to increase with age (R2  0.38) and
a nonsignificant trend to decrease with achieved sys-
FIGURE 1. Heart failure events associated with ACE inhibitors (ACE-I) and drugs with dif-
ferent mechanisms of action in patients with essential hypertension. ABCD  Appropriate
Blood Pressure Control in Diabetes; ANBP2  Second Australian National Blood Pressure
Study Group; CAPPP  Captopril Prevention Project; STOP-2 Swedish Trial in Old Pa-
tients with Hypertension-2 study; UKPDS  UK Prospective Diabetes Study Group.
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TABLE 1 Characteristics of Trials Comparing Angiotensin-Converting Enzyme (ACE) Inhibitors With Different Antihypertensive Drugs
Characteristics UKPDS 398 ABCD9 STOP-210 CAPPP11 ALLHAT6,7 ANBP25
Yr of publication 1998 1998 1999 1999 2000, 2002 2003
Diabetes mellitus      
Demographic characteristics
No. of patients (ACE-I/others) 400/358 235/235 2,205/4,409 5,492/5,493 9,054/24,316 3,044/3,039
Age in years (ACE-I/others) 56.3/56.0 57.7/57.2 76.1/75.9 52.4/52.7 66.9/66.9 72/72.9
% Men (ACE-I/others) 51/57 50/47 34/33 55/52 46/47 50/48
Type of treatment
ACE-I Captopril Enalapril Enalapril/lisinopril Captopril Lisinopril Enalapril
Reference drugs Atenolol Nisoldipine  blockers/diuretic/
CCB
-blockers/diuretic Amlodipine/chortalidone/
doxazosin
Diuretics
Add-on drugs Furosemide, nifedipine,
methyldopa,
prazosin
Metoprolol, diuretics Diuretics,  blockers Ca-antagonists,
diuretics
Atenolol, idralazine,
resrpine, clonidine
-blockers, Ca-
antagonists,
-blockers
No. of CHF events during follow-up
ACE-I/others 12/9 5/6 149/363 75/66 612/2,067 69/78
Systolic BP at baseline in mm Hg
(ACE-I/others)
159/159 156/155 194/194 162/160 146/146 167/168
Difference in achieved systolic BP in mm Hg
(ACE-I minus others)
1 1 0.5 3 1.3 1
Follow-up (yrs) 8.4 5.6 4.5 6.1 4.9 4.1
ACE-I  angiotensin converting enzyme inhibitor; BP  blood pressure; CCB  calcium channel blocker; CHF  congestive heart failure; other abbreviations as in Figure 1.
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tolic blood pressure (R2  0.33). These associations
were not statistically significant, possibly because of
the limited numbers of reviewed studies. However,
these trends raise the hypothesis that ACE inhibitors
may provide greater potential benefits for CHF pre-
vention in elderly hypertensive subjects as well as in
those with a better control of systolic blood pressure
who are using treatment.
Our results extend those of a recent meta-analysis
by Staessen et al,12 who limited their assessment to the
effects of ACE inhibitors versus conventional drugs
(diuretics and/or  blockers) in some of the trials
considered in this report. The risk of CHF did not
differ between subjects randomized to receive ACE
inhibitors and subjects randomized to receive diuretics
and/or  blockers (p 0.64).12 Notably, our overview
allows us to extend these conclusions to all antihyper-
tensive drugs that are different from ACE inhibitors,
including calcium-channel blockers and -1 blockers.
Although there was no significant heterogeneity
across the studies (chi-square 9.05; degree of freedom
5; p  0.11), diagnoses of CHF were not uniform. In
5 studies,5,8,9–11 adjudication of CHF events was made
by an independent end-point committee whose mem-
bers were blinded to the treatment group. In all of
these studies, adjudication of CHF required subject
admission to the hospital. In 1 study,7 diagnosis of
CHF was left up to individual investigators, with 1.9%
of CHF events in that study7 reviewed by a commit-
tee.13
The mean duration of follow-up, 5 years in half
of the studies, may have been too short to disclose a
protective effect of long-term ACE inhibition on the
prevention of CHF. In addition, ACE inhibitors may
have failed to fully suppress the activity of the renin–
angiotensin system during long-term treatment be-
cause of activation of other angiotensin-II–generating
pathways.14,15 Angiotensin II reactivation and failure
of aldosterone suppression have been found in up to
38% of patients with CHF taking an ACE inhibitor.14
These phenomena have been ascribed to poor compli-
ance with therapy in patients with low levels of ACE
inhibition or to activation of alternative angiotensin-
II–generating pathways in those with low ACE and
high angiotensin II concentrations.14 The frequency of
angiotensin II reactivation and failure of aldosterone
suppression in apparently healthy subjects with essen-
tial hypertension treated with ACE inhibitors are un-
known.
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